Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sphingosine 1-phosphate receptor 1signaling in macrophages reduces atherosclerosis in LDL receptor-deficient mice.
Potì F, Scalera E, Feuerborn R, Fischer J, Arndt L, Varga G, Pardali E, Seidl MD, Fobker M, Liebisch G, Hesse B, Lukasz AH, Rossaint J, Kehrel BE, Rosenbauer F, Renné T, Christoffersen C, Simoni M, Burkhardt R, Nofer JR. Potì F, et al. Among authors: arndt l. JCI Insight. 2024 Dec 20;9(24):e158127. doi: 10.1172/jci.insight.158127. JCI Insight. 2024. PMID: 39531328 Free PMC article.
The Role of IL-13 and IL-4 in Adipose Tissue Fibrosis.
Arndt L, Lindhorst A, Neugebauer J, Hoffmann A, Hobusch C, Alexaki VI, Ghosh A, Blüher M, Wolfrum C, Glaß M, Gericke M. Arndt L, et al. Int J Mol Sci. 2023 Mar 16;24(6):5672. doi: 10.3390/ijms24065672. Int J Mol Sci. 2023. PMID: 36982747 Free PMC article.
Supercurrent in Bi4Te3 Topological Material-Based Three-Terminal Junctions.
Kölzer J, Jalil AR, Rosenbach D, Arndt L, Mussler G, Schüffelgen P, Grützmacher D, Lüth H, Schäpers T. Kölzer J, et al. Among authors: arndt l. Nanomaterials (Basel). 2023 Jan 10;13(2):293. doi: 10.3390/nano13020293. Nanomaterials (Basel). 2023. PMID: 36678045 Free PMC article.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Razonable RR, et al. Among authors: arndt l. Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23. Mayo Clin Proc. 2022. PMID: 36058578 Free PMC article.
49 results